Sundhedspolitik

Følg
SPD politicians criticizing Health Minister Nina Warken's unbalanced health savings package in Bundestag debate, demanding pharma cuts.
Billede genereret af AI

SPD kritiserer ubalance i Warkens sundhedsbesparelsespakke

Rapporteret af AI Billede genereret af AI

Få dage før den planlagte kabinetsbeslutning advarer SPD mod at belaste de forsikrede for hårdt med sundhedsminister Nina Warkens sparepakke. SPD kræver flere besparelser hos medicinalvirksomheder og tiltag for effektivisering. De Grønne har præsenteret deres eget modforslag.

The Korean government's plan to extend National Health Insurance coverage to hair-loss medication is facing growing criticism from patient groups and medical experts.

Rapporteret af AI

Forbundssundhedsminister Nina Warken har opfordret delstaterne til at sænke bygningsstandarderne for plejehjem. Målet er at reducere udgifterne til pleje.

I et interview med RND diskuterer Klaus Reinhardt, præsident for Den tyske lægeforening, de høje besøgstal hos læger i Tyskland, som han ikke alene tilskriver patienternes adfærd. Han advarer mod planlagte receptere sådde rettigheder for apotekere og går ind for sukkerafgift samt forbud mod smartphones i skoler. Desuden støtter han ny regulering af assisteret selvmord med strenge beskyttelsestiltag.

Rapporteret af AI Faktatjekket

Actress Cheryl Hines said in a recent interview with Dr. Phil McGraw that her husband, Health and Human Services Secretary Robert F. Kennedy Jr., at one point suggested the couple publicly claim they were separated to reduce the political backlash she was facing. Hines said she did not consider doing so.

In the second Trump administration, Heritage Foundation scholars are pressing Health and Human Services Secretary Robert F. Kennedy Jr. to order "gold standard" studies and expand informed-consent requirements for oral contraceptives, arguing the pills carry underappreciated health and ecological costs.

Rapporteret af AI

A U.S. federal judge has ruled that the Food and Drug Administration (FDA) possesses the authority to regulate lab-developed tests (LDTs) as medical devices. This decision comes amid ongoing debates over the oversight of in-house diagnostic tools used by clinical laboratories.

 

 

 

Dette websted bruger cookies

Vi bruger cookies til analyse for at forbedre vores side. Læs vores privatlivspolitik for mere information.
Afvis